Phase II clinical trials have shown that enzalutamide in combination with trastuzumab has shown significant benefit for high stage or locally advanced HER2+/AR+ breast cancer (NCT02091960[102], https://clinicaltrials.gov/ct2/show/NCT02091960). The gene discussed is AR; the disease is breast carcinoma.